We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ionis Pharmaceuticals (IONS) Reports Q3 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
Ionis Pharmaceuticals (IONS - Free Report) reported $243 million in revenue for the quarter ended September 2026, representing a year-over-year increase of 54.8%. EPS of -$0.40 for the same period compares to -$0.61 a year ago.
The reported revenue represents a surprise of +35.81% over the Zacks Consensus Estimate of $178.93 million. With the consensus EPS estimate being -$1.00, the EPS surprise was +60%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Total commercial revenue: $136 million versus the eight-analyst average estimate of $140.09 million. The reported number represents a year-over-year change of +17.2%.
Revenue- Product sales, net: $48 million versus the eight-analyst average estimate of $56.46 million. The reported number represents a year-over-year change of +50%.
Revenue- Total research and development revenue: $107 million versus the eight-analyst average estimate of $38.84 million. The reported number represents a year-over-year change of +161%.
Revenue- Royalty revenue- SPINRAZA royalties: $69 million versus the seven-analyst average estimate of $55.98 million. The reported number represents a year-over-year change of +23.2%.
Revenue- Commercial revenue- Other commercial revenue: $7 million versus the seven-analyst average estimate of $5.16 million. The reported number represents a year-over-year change of -12.5%.
Revenue- Royalty revenue- WAINUA royalties: $7 million compared to the $17.67 million average estimate based on seven analysts.
Revenue- Royalty revenue: $81 million compared to the $78.28 million average estimate based on seven analysts.
Revenue- Product sales net- DAWNZERA sales: $37 million versus $33.15 million estimated by seven analysts on average.
Revenue- Product sales net- TRYNGOLZA sales: $9 million compared to the $23.09 million average estimate based on seven analysts.
Revenue- Royalty revenue- Other royalties: $5 million compared to the $3.96 million average estimate based on six analysts. The reported number represents a change of -28.6% year over year.
Revenue- Research and development revenue- WAINUA joint development revenue: $4 million compared to the $13.7 million average estimate based on five analysts.
Revenue- Research and development revenue- Collaborative agreement revenue: $103 million compared to the $19 million average estimate based on five analysts. The reported number represents a change of +232.3% year over year.
Shares of Ionis Pharmaceuticals have returned -12.9% over the past month versus the Zacks S&P 500 composite's -5.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
View the Zacks #1 Rank List
Image: Bigstock
Ionis Pharmaceuticals (IONS) Reports Q3 Earnings: What Key Metrics Have to Say
Ionis Pharmaceuticals (IONS - Free Report) reported $243 million in revenue for the quarter ended September 2026, representing a year-over-year increase of 54.8%. EPS of -$0.40 for the same period compares to -$0.61 a year ago.
The reported revenue represents a surprise of +35.81% over the Zacks Consensus Estimate of $178.93 million. With the consensus EPS estimate being -$1.00, the EPS surprise was +60%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Ionis Pharmaceuticals here>>>
Shares of Ionis Pharmaceuticals have returned -12.9% over the past month versus the Zacks S&P 500 composite's -5.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.